7 Results for "

Peptide-Drug Conjugates (PDCs)

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Peptide-Drug Conjugates (PDCs)" in MCE Product Catalog:

Cat. No.: HY-P10762
CAS No.: 2082631-84-1
Synonyms: CBP-1008; LDC 10B
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
loading...
    loading...
Cat. No.: HY-P10740
CAS No.: 2923068-30-6
CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-P10741
CAS No.: 2151063-66-8
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-178489
Target:  

Nectin-4

Research Areas:  

Cancer

BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
loading...
    loading...
Cat. No.: HY-P11018
Research Areas:  

Cancer

(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
loading...
    loading...
Cat. No.: HY-106195
CAS No.: 207395-85-5
L 377202 is a peptide-drug conjugate (PDC). L 377202 consists of Doxorubicin (HY-15142A) and a prostate-specific antigen (PSA)-hydrolyzable peptide. L 377202 demonstrates strong inhibitory effects on PSA-secreting prostate cancer cells. L 377202 is promising for research of prostate cancer .
loading...
    loading...
Cat. No.: HY-188016
CAS No.: 3086791-83-2
Research Areas:  

Others

MC-GGFG-TriPtolide is a peptide-drug conjugate (PDC) composed of a cell-penetrating peptide (MC), a cathepsin-cleavable GGFG peptide linker, and the payload drug Triptolide (HY-32735), and it is used for targeted intracellular delivery .
loading...
    loading...